IL1B and breast cancer: We recently identified the pro-inflammatory cytokine Interleukin-1B (IL-1B) as a marker of breast cancer bone metastasis and showed that pharmacological targeting of IL-1B or its receptor (IL1R1) impairs bone metastasis10–13.